We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Antipsychotika | SpringerLink
Skip to main content
SpringerLink
Log in

Antipsychotika

  • Chapter
Book cover Kompendium der Psychiatrischen Pharmakotherapie

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Antipsychotika im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben. Ein Schwerpunkt liegt in der ausführlichen Darstellung der Risiken und Nebenwirkungen der Antipsychotika. Lorazepam und Loxapin sind als neue Antipsychotika eingeführt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Andreasen NC, Liu D, Ziebell S et al (2013) Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 170(6): 609–615

    Google Scholar 

  • Berling I, Isbister GK (2015) Prolonged QT risk assessment in antipsychotic overdose using the QT nomogram. Ann Emerg Med 66(2): 154–164

    Google Scholar 

  • Borlido C, Remington G, Graff-Guerrero A et al (2016) Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized double-blind, placebo-controlled study. J Clin Psychiatry 77: e14–20

    Google Scholar 

  • Correll CU, Joffe BI, Rosen LM et al (2015) Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry 14: 56–63

    Google Scholar 

  • DGPPN (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde) (Hrsg) (2006) Behandlungsleitlinie Schizophrenie. Reihe: S3 Praxisleitlinien in Psychiatrie und Psychotherapie, Bd 1. Springer, Berlin Heidelberg New York

    Google Scholar 

  • Dold M, Li C, Gillies D, Leucht S (2013) Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol 23: 1023–1033

    Google Scholar 

  • Dunk LR, Annan LJ, Andrews CD (2006) Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 188: 255–263

    Google Scholar 

  • Farahani A, Correll CU (2012) Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry 73(4): 486–496

    Google Scholar 

  • Fink A, Cieslak S, Rosenbach F (2015) Nichtpharmakologische Interventionen zur Prävention von Gewichtszunahme bei schizophrenen Patienten unter antispychotischer Medikation. Psychiat Prax 42: 359–369

    Google Scholar 

  • Fusar-Poli P, Papanastasiou E, Stahl D et al (2015) Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schiz Bull 41: 892–899

    Google Scholar 

  • Furukawa TA, Levine SZ, Tanaka S et al (2015) Initial severity of schizophrenia and efficacy of antipsychotics. JAMA Psychiatry 72: 14–21

    Google Scholar 

  • Gallego JA, Bonetti J, Zhang J et al (2012) Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 138: 18–28

    Google Scholar 

  • Gareri P, De Fazio P, Manfredi VG et al (2014) Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol 34(1): 109–123

    Google Scholar 

  • Harrow M, Jobe TH (2013) Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophr Bull 39(5): 962–965

    Google Scholar 

  • Hasan A, Wobrock T, Gaebel W et al (2013) Nationale und internationale Leitlinien zur Schizophrenie. Nervenarzt 84: 1359–1368

    Google Scholar 

  • Hasnain M, Vieweg WV (2014) QTc interval prolongation and Torsade de Pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs 28: 887–920

    Google Scholar 

  • Hsieh PH, Hsiao FY, Gau SS, Gau CS (2013) Use of antipsychotics and risk of cerebrovascular events in schizophrenic patients: a nested case-control study. J Clin Psychopharmacol 33(3): 299–305

    Google Scholar 

  • Hwang YJ, Dixon SN, Reiss JP et al (2014) Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med 161: 242–248

    Google Scholar 

  • Jarskog LF, Hamer RM, Catellier DJ (2013) Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 170(9): 1032–1040

    Google Scholar 

  • Jauhar S, McKenna PJ, Radua J et al (2014) Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry 204: 20–29

    Google Scholar 

  • Kane JM, Correll CU (2016) The role of clozapine in treatment-resistant schizophrenia. JAMA Psychiatry 73(3): 187–188

    Google Scholar 

  • Kane JM, Kishimoto T, Correll CU (2013) Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry 12: 216–226

    Google Scholar 

  • Kelly TM, Daley DC, Douaihy AB (2012) Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav 37(1): 11–24

    Google Scholar 

  • Kishimoto T, Agarwal V, Kishi T et al (2013a) Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 18(1): 53–66

    Google Scholar 

  • Kishimoto T, Nitta M, Borenstein M et al (2013b) Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74(10): 957–965

    Google Scholar 

  • Kishimoto T, Robenzadeh A, Leucht C et al (2014) Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 40: 192–213

    Google Scholar 

  • Klosterkötter J (2013) Prävention psychotischer Störungen. Nervenarzt 84(11): 1299–1309

    Google Scholar 

  • Knöchel C, Reuter J, Reinke B et al (2016) Cortical thinning in bipolar disorder and schizophrenia. Schizophr Res 172(1–3): 78–85

    Google Scholar 

  • Kristensen D, Hageman I, Bauer J et al (2013) Antipsychotic polypharmacy in a treatment-refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy. J ECT 29: 271–276

    Google Scholar 

  • Lahdelma L, Appelberg B (2012) Clozapine-induced agranulocytosis in Finland, 1982–2007: long-term monitoring of patients is still warranted. J Clin Psychiatry 73(6): 837–742

    Google Scholar 

  • Lederbogen F, Schwarz P, Häfner S et al (2015) Kardiale und metabolische Risikofaktoren bei schweren psychischen Erkrankungen. Nervenarzt 86: 866–871

    Google Scholar 

  • Lesh TA, Tanase C, Gelb BR et al (2015) A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia. JAMA Psychiatry 72: 226–234

    Google Scholar 

  • Leucht C, Heres S, Kane JM et al (2011) Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127(1–3): 83–92

    Google Scholar 

  • Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896): 951–962

    Google Scholar 

  • Leucht S, Samara M, Heres S et al (2014) Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 40(2): 314–326

    Google Scholar 

  • Lopez OL, Becker JT, Chang YF et al (2013) The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer’s disease. Am J Psychiatry 170(9): 1051–1058

    Google Scholar 

  • Mahmood S, Booker I, Huang J, Coleman CI (2013) Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol 33: 90–94

    Google Scholar 

  • Maust DT, Kim HM, Seyfried LS et al (2015) Antipsychotics, other psychotropics, and the risk of death in patients with dementia. JAMA Psychiatry 72: 438–445

    Google Scholar 

  • Meyer N, Gee S, Whiskey E et al (2015) Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis. J Clin Psychiatry 76: e1410–1416

    Google Scholar 

  • Morgan CJA, Freeman TP, Powell J et al (2016) AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. Transl Psychiatry 6: e738

    Google Scholar 

  • Nielsen J, Damkier P, Lublin H et al (2011) Optimizing clozapine treatment. Acta Psychiatr Scand 123: 411–422

    Google Scholar 

  • Nielsen J, Correll CU, Manu P et al (2013) Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry 74: 603–613

    Google Scholar 

  • Osser DN, Roudsari MJ, Manschreck T (2013) The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry 21: 18–40

    Google Scholar 

  • Parabiaghi A, Tettamanti M, D’Avanzo B et al (2016) Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. Acta Psychiatr Scand 133: 63–75

    Google Scholar 

  • Porcelli S, Balzarro B, Serretti A (2012) Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 22(3):165–182

    Google Scholar 

  • Samara MT, Leucht C, Leeflang MM et al (2015) Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 172: 617–629

    Google Scholar 

  • Samara MT, Dold M, Gianatsi M et al (2016) Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry 73(3): 199–210

    Google Scholar 

  • Schennach R, Riesbeck M, Mayr A et al (2013) Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients? Acta Psychiatr Scand 127: 474–481

    Google Scholar 

  • Sommer IE, Begemann MJ, Temmerman A et al (2012) Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 38: 1003–1011

    Google Scholar 

  • Steinert T, Baier H, Fröscher W, Jandl M (2011) Epileptische Anfälle unter der Behandlung mit Antidepressiva und Neuroleptika. Fortschr Neurol Psychiatr 79(3): 138–143

    Google Scholar 

  • Tang JY, Chang WC, Hui CL et al (2014) Prospective relationship between duration of untreated psychosis and 13-year clinical outcome: a first-episode psychosis study. Schizophr Res 153: 1–8

    Google Scholar 

  • Taylor DM, Smith L, Gee SH et al (2012) Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatr Scand 125: 15–24

    Google Scholar 

  • Tiihonen J, Mittendorfer-Rutz E, Torniainen M et al (2015) Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry [Epub ahed of print]

    Google Scholar 

  • Torniainen M, Mittendorfer-Rutz E, Tanskanen A et al (2015) Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 41: 656–636

    Google Scholar 

  • Utzerath G, Reske D, Gouzoulis-Mayfrank E (2015) Parenteral applizierte Antipsychotika bei Agitation und Aggresion. Fortschr Neurol Psychiatr 83: 665–675

    Google Scholar 

  • Wenzel-Seifert K, Wittmann M, Haen E (2011) QTc prolongation by psychotropic drugs and the risk of Torsades de Pointes. Dtsch Arztebl Int 108(41): 687–693

    Google Scholar 

  • Wu CS, Wang SC, Gau SS et al (2013) Association of stroke with the receptor-binding profiles of antipsychotics-a case-crossover study. Biol Psychiatry 73(5): 414–421

    Google Scholar 

  • Wunderink L, Nieboer RM, Wiersma D et al (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70(9): 913–920

    Google Scholar 

  • Zipursky RB, Menezes NM, Streiner DL (2014) Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 152: 408–414

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Marburg/Gießen

    Prof. Dr. med. Dr. rer. nat. Dipl.-Psych. M. J. Müller

  2. Mainz

    Prof. Dr. med. O. Benkert

Authors
  1. Prof. Dr. med. Dr. rer. nat. Dipl.-Psych. M. J. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. O. Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mainz

    Otto Benkert

  2. München

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Müller, M., Benkert, O. (2017). Antipsychotika. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50333-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-50333-1_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-50332-4

  • Online ISBN: 978-3-662-50333-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation